###begin article-title 0
The behavior of osteoblast-like cells on various substrates with functional blocking of integrin-beta1 and integrin-beta3
###end article-title 0
###begin p 1
This study was designed to examine the influence of integrin subunit-beta1 and subunit-beta3 on the behavior of primary osteoblast-like cells, cultured on calcium phosphate (CaP)-coated and non coated titanium (Ti). Osteoblast-like cells were incubated with specific monoclonal antibodies against integrin-beta1 and integrin-beta3 to block the integrin function. Subsequently, cells were seeded on Ti discs, either non coated or provided with a 2 mum carbonated hydroxyapatite coating using Electrostatic Spray Deposition. Results showed that on CaP coatings, cellular attachment was decreased after a pre-treatment with either anti-integrin-beta1 or anti-integrin-beta3 antibodies. On Ti, cell adhesion was only slightly affected after a pre-treatment with anti-integrin-beta3 antibodies. Scanning electron microscopy showed that on both types of substrate, cellular morphology was not changed after a pre-treatment with either antibody. With quantitative PCR, it was shown for both substrates that mRNA expression of integrin-beta1 was increased after a pre-treatment with either anti-integrin-beta1 or anti-integrin-beta3 antibodies. Furthermore, after a pre-treatment with either antibody, mRNA expression of integrin-beta3 and ALP was decreased, on both types of substrate. In conclusion, osteoblast-like cells have the ability to compensate to great extent for the blocking strategy as applied here. Still, integrin-beta1 and beta3 seem to play different roles in attachment, proliferation, and differentiation of osteoblast-like cells, and responses on CaP-coated substrates differ to non coated Ti. Furthermore, the influence on ALP expression suggests involvement of both integrin subunits in signal transduction for cellular differentiation.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
For implants used in orthopedic or dental surgery the implant-to-bone contact is influenced by the characteristics of the implant, like the surface structure and chemical composition. Regarding the latter, calcium phosphate (CaP) coatings have shown to favor the bone response in vivo [1, 2]. However, the mechanism responsible for the improved osteogenic response to CaP coatings is still not clear. Studying the mechanism in vivo is complicated by many factors. Still, cell culture models can be designed to study (parts of) the underlying mechanisms.
###end p 3
###begin p 4
###xml 404 405 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 417 418 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 506 507 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 785 786 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 978 979 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1093 1100 1043 1050 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1169 1170 1119 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1100 1171 1050 1121 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="5">An overview of possible integrin subunits and their protein ligands [<xref ref-type="bibr" rid="CR2">2</xref>]</p>
###xml 1100 1171 1050 1121 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="5">An overview of possible integrin subunits and their protein ligands [<xref ref-type="bibr" rid="CR2">2</xref>]</p></caption>
###xml 1171 1179 1121 1129 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Subunits</th>
###xml 1179 1186 1129 1136 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Ligands</th>
###xml 1171 1186 1121 1136 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Subunits</th><th align="left">Ligands</th></tr>
###xml 1171 1186 1121 1136 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" colspan="2">Subunits</th><th align="left">Ligands</th></tr></thead>
###xml 1186 1191 1136 1138 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="10">&#946;1</td>
###xml 1191 1197 1138 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;1</td>
###xml 1197 1216 1140 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Collagens, Laminins</td>
###xml 1186 1216 1136 1159 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="10">&#946;1</td><td align="left">&#945;1</td><td align="left">Collagens, Laminins</td></tr>
###xml 1216 1222 1159 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;2</td>
###xml 1222 1241 1161 1180 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Collagens, Laminins</td>
###xml 1216 1241 1159 1180 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;2</td><td align="left">Collagens, Laminins</td></tr>
###xml 1241 1247 1180 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;3</td>
###xml 1247 1277 1182 1212 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibronectin, Collagen, Laminin</td>
###xml 1241 1277 1180 1212 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;3</td><td align="left">Fibronectin, Collagen, Laminin</td></tr>
###xml 1277 1283 1212 1214 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;4</td>
###xml 1283 1300 1214 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibronectin, VCAM</td>
###xml 1277 1300 1212 1231 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;4</td><td align="left">Fibronectin, VCAM</td></tr>
###xml 1300 1306 1231 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;5</td>
###xml 1306 1317 1233 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibronectin</td>
###xml 1300 1317 1231 1244 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;5</td><td align="left">Fibronectin</td></tr>
###xml 1317 1323 1244 1246 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;6</td>
###xml 1323 1331 1246 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Laminins</td>
###xml 1317 1331 1244 1254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;6</td><td align="left">Laminins</td></tr>
###xml 1331 1337 1254 1256 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;7</td>
###xml 1337 1345 1256 1264 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Laminins</td>
###xml 1331 1345 1254 1264 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;7</td><td align="left">Laminins</td></tr>
###xml 1345 1351 1264 1266 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;8</td>
###xml 1351 1362 1266 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibronectin</td>
###xml 1345 1362 1264 1277 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;8</td><td align="left">Fibronectin</td></tr>
###xml 1362 1368 1277 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;9</td>
###xml 1368 1389 1279 1300 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tenascin, Osteopontin</td>
###xml 1362 1389 1277 1300 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;9</td><td align="left">Tenascin, Osteopontin</td></tr>
###xml 1389 1395 1300 1302 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#913;v</td>
###xml 1395 1419 1302 1326 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibronectin, Vitronectin</td>
###xml 1389 1419 1300 1326 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#913;v</td><td align="left">Fibronectin, Vitronectin</td></tr>
###xml 1419 1424 1326 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">&#946;2</td>
###xml 1424 1430 1328 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#913;L</td>
###xml 1430 1435 1330 1335 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ICAMs</td>
###xml 1419 1435 1326 1335 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">&#946;2</td><td align="left">&#913;L</td><td align="left">ICAMs</td></tr>
###xml 1435 1441 1335 1337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;M</td>
###xml 1441 1451 1337 1347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrinogen</td>
###xml 1435 1451 1335 1347 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#945;M</td><td align="left">Fibrinogen</td></tr>
###xml 1451 1457 1347 1349 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#913;X</td>
###xml 1457 1467 1349 1359 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrinogen</td>
###xml 1451 1467 1347 1359 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#913;X</td><td align="left">Fibrinogen</td></tr>
###xml 1467 1472 1359 1361 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">&#946;3</td>
###xml 1472 1475 1361 1364 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Iib</td>
###xml 1475 1511 1364 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrinogen, Fibronectin, Vitronectin</td>
###xml 1467 1511 1359 1400 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="2">&#946;3</td><td align="left">Iib</td><td align="left">Fibrinogen, Fibronectin, Vitronectin</td></tr>
###xml 1511 1517 1400 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#913;v</td>
###xml 1517 1558 1402 1443 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibrinogen, Fibronectin, Vitronectin, BSP</td>
###xml 1511 1558 1400 1443 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#913;v</td><td align="left">Fibrinogen, Fibronectin, Vitronectin, BSP</td></tr>
###xml 1558 1563 1443 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#946;4</td>
###xml 1563 1569 1445 1447 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;6</td>
###xml 1569 1576 1447 1454 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Laminin</td>
###xml 1558 1576 1443 1454 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#946;4</td><td align="left">&#945;6</td><td align="left">Laminin</td></tr>
###xml 1576 1581 1454 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#946;5</td>
###xml 1581 1587 1456 1458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#913;v</td>
###xml 1587 1598 1458 1469 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Vitronectin</td>
###xml 1576 1598 1454 1469 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#946;5</td><td align="left">&#913;v</td><td align="left">Vitronectin</td></tr>
###xml 1598 1603 1469 1471 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#946;6</td>
###xml 1603 1609 1471 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#913;v</td>
###xml 1609 1620 1473 1484 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fibronectin</td>
###xml 1598 1620 1469 1484 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#946;6</td><td align="left">&#913;v</td><td align="left">Fibronectin</td></tr>
###xml 1186 1620 1136 1484 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="10">&#946;1</td><td align="left">&#945;1</td><td align="left">Collagens, Laminins</td></tr><tr><td align="left">&#945;2</td><td align="left">Collagens, Laminins</td></tr><tr><td align="left">&#945;3</td><td align="left">Fibronectin, Collagen, Laminin</td></tr><tr><td align="left">&#945;4</td><td align="left">Fibronectin, VCAM</td></tr><tr><td align="left">&#945;5</td><td align="left">Fibronectin</td></tr><tr><td align="left">&#945;6</td><td align="left">Laminins</td></tr><tr><td align="left">&#945;7</td><td align="left">Laminins</td></tr><tr><td align="left">&#945;8</td><td align="left">Fibronectin</td></tr><tr><td align="left">&#945;9</td><td align="left">Tenascin, Osteopontin</td></tr><tr><td align="left">&#913;v</td><td align="left">Fibronectin, Vitronectin</td></tr><tr><td align="left" rowspan="3">&#946;2</td><td align="left">&#913;L</td><td align="left">ICAMs</td></tr><tr><td align="left">&#945;M</td><td align="left">Fibrinogen</td></tr><tr><td align="left">&#913;X</td><td align="left">Fibrinogen</td></tr><tr><td align="left" rowspan="2">&#946;3</td><td align="left">Iib</td><td align="left">Fibrinogen, Fibronectin, Vitronectin</td></tr><tr><td align="left">&#913;v</td><td align="left">Fibrinogen, Fibronectin, Vitronectin, BSP</td></tr><tr><td align="left">&#946;4</td><td align="left">&#945;6</td><td align="left">Laminin</td></tr><tr><td align="left">&#946;5</td><td align="left">&#913;v</td><td align="left">Vitronectin</td></tr><tr><td align="left">&#946;6</td><td align="left">&#913;v</td><td align="left">Fibronectin</td></tr></tbody>
###xml 1171 1620 1121 1484 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Subunits</th><th align="left">Ligands</th></tr></thead><tbody><tr><td align="left" rowspan="10">&#946;1</td><td align="left">&#945;1</td><td align="left">Collagens, Laminins</td></tr><tr><td align="left">&#945;2</td><td align="left">Collagens, Laminins</td></tr><tr><td align="left">&#945;3</td><td align="left">Fibronectin, Collagen, Laminin</td></tr><tr><td align="left">&#945;4</td><td align="left">Fibronectin, VCAM</td></tr><tr><td align="left">&#945;5</td><td align="left">Fibronectin</td></tr><tr><td align="left">&#945;6</td><td align="left">Laminins</td></tr><tr><td align="left">&#945;7</td><td align="left">Laminins</td></tr><tr><td align="left">&#945;8</td><td align="left">Fibronectin</td></tr><tr><td align="left">&#945;9</td><td align="left">Tenascin, Osteopontin</td></tr><tr><td align="left">&#913;v</td><td align="left">Fibronectin, Vitronectin</td></tr><tr><td align="left" rowspan="3">&#946;2</td><td align="left">&#913;L</td><td align="left">ICAMs</td></tr><tr><td align="left">&#945;M</td><td align="left">Fibrinogen</td></tr><tr><td align="left">&#913;X</td><td align="left">Fibrinogen</td></tr><tr><td align="left" rowspan="2">&#946;3</td><td align="left">Iib</td><td align="left">Fibrinogen, Fibronectin, Vitronectin</td></tr><tr><td align="left">&#913;v</td><td align="left">Fibrinogen, Fibronectin, Vitronectin, BSP</td></tr><tr><td align="left">&#946;4</td><td align="left">&#945;6</td><td align="left">Laminin</td></tr><tr><td align="left">&#946;5</td><td align="left">&#913;v</td><td align="left">Vitronectin</td></tr><tr><td align="left">&#946;6</td><td align="left">&#913;v</td><td align="left">Fibronectin</td></tr></tbody></table>
###xml 1093 1620 1043 1484 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="5">An overview of possible integrin subunits and their protein ligands [<xref ref-type="bibr" rid="CR2">2</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Subunits</th><th align="left">Ligands</th></tr></thead><tbody><tr><td align="left" rowspan="10">&#946;1</td><td align="left">&#945;1</td><td align="left">Collagens, Laminins</td></tr><tr><td align="left">&#945;2</td><td align="left">Collagens, Laminins</td></tr><tr><td align="left">&#945;3</td><td align="left">Fibronectin, Collagen, Laminin</td></tr><tr><td align="left">&#945;4</td><td align="left">Fibronectin, VCAM</td></tr><tr><td align="left">&#945;5</td><td align="left">Fibronectin</td></tr><tr><td align="left">&#945;6</td><td align="left">Laminins</td></tr><tr><td align="left">&#945;7</td><td align="left">Laminins</td></tr><tr><td align="left">&#945;8</td><td align="left">Fibronectin</td></tr><tr><td align="left">&#945;9</td><td align="left">Tenascin, Osteopontin</td></tr><tr><td align="left">&#913;v</td><td align="left">Fibronectin, Vitronectin</td></tr><tr><td align="left" rowspan="3">&#946;2</td><td align="left">&#913;L</td><td align="left">ICAMs</td></tr><tr><td align="left">&#945;M</td><td align="left">Fibrinogen</td></tr><tr><td align="left">&#913;X</td><td align="left">Fibrinogen</td></tr><tr><td align="left" rowspan="2">&#946;3</td><td align="left">Iib</td><td align="left">Fibrinogen, Fibronectin, Vitronectin</td></tr><tr><td align="left">&#913;v</td><td align="left">Fibrinogen, Fibronectin, Vitronectin, BSP</td></tr><tr><td align="left">&#946;4</td><td align="left">&#945;6</td><td align="left">Laminin</td></tr><tr><td align="left">&#946;5</td><td align="left">&#913;v</td><td align="left">Vitronectin</td></tr><tr><td align="left">&#946;6</td><td align="left">&#913;v</td><td align="left">Fibronectin</td></tr></tbody></table></table-wrap>
In vitro, it is known that cells attach to extracellular matrix (ECM) proteins, which are adsorbed to the surface of the material. Specific transmembrane proteins, called integrins, connect the cells to the ECM proteins. These integrins consist of an alpha- and a beta-unit. Osteoblasts generally express integrin subunits alpha1, alpha2, alpha3, alpha4, alpha5, alpha6, alphav, beta1, beta3, and beta5 [3]. In Table 1, an overview is listed of combinations of integrin subunits and their protein ligands [4]. Important ECM proteins for the attachment of osteoblasts are fibronectin, collagen type I, and vitronectin. For attachment to fibronectin and collagen type I, osteoblasts can express integrin subunit-beta1. For attachment to vitronectin, they may use integrin subunit-beta3 [5]. Once cells have attached, the integrin is also involved in passing information from the ECM to the cell ("outside-in-signaling"), and from the cell towards the ECM ("inside-out-signaling) [6]. These signaling pathways can regulate cellular adhesion, migration, and subsequent behavior to a great extent. Table 1An overview of possible integrin subunits and their protein ligands [2]SubunitsLigandsbeta1alpha1Collagens, Lamininsalpha2Collagens, Lamininsalpha3Fibronectin, Collagen, Lamininalpha4Fibronectin, VCAMalpha5Fibronectinalpha6Lamininsalpha7Lamininsalpha8Fibronectinalpha9Tenascin, OsteopontinAlphavFibronectin, Vitronectinbeta2AlphaLICAMsalphaMFibrinogenAlphaXFibrinogenbeta3IibFibrinogen, Fibronectin, VitronectinAlphavFibrinogen, Fibronectin, Vitronectin, BSPbeta4alpha6Lamininbeta5AlphavVitronectinbeta6AlphavFibronectin
###end p 4
###begin p 5
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
An overview of possible integrin subunits and their protein ligands [2]
###end p 5
###begin p 6
In this study the importance of integrins in the bone-implant-interface was examined on two different implant materials (either CaP-coated or non coated Ti), with the functional blocking of integrins. We hypothesize that blocking integrin-beta1 and integrin-beta3 with specific antibodies will have an inhibitory effect on the initial attachment, and thus will delay proliferation and early differentiation of osteoblast-like cells. Furthermore, we hypothesize that differences in cellular response exist between cultures on CaP coatings and non coated Ti. For this purpose, carbonated hydroxyapatite (HA) coatings were deposited with the electrostatic spray deposition (ESD) technique. Subsequently, anti-integrin-beta1 and anti-integrin-beta3 antibodies were added to primary osteoblast-like cells, and cells were cultured on both substrates. The initial cellular attachment, proliferation, and cell shape were evaluated. Further, gene expression for integrins beta1 and beta3, and alkaline phosphatase, was examined with quantitative PCR. Results were compared to cultures without antibodies added to the cells on both materials.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Substrates
###end title 8
###begin p 9
Disc-shaped commercially pure (cp) Ti substrates with a diameter of 12 mm and a thickness of 1.5 mm were cleaned ultrasonically in isopropanol for 5 min. Subsequently, the substrates were not coated, or provided with a CaP coating using the ESD technique.
###end p 9
###begin p 10
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 242 243 242 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 244 245 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 250 251 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 265 266 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 268 269 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
The ESD coating procedure was performed using a vertical ESD set-up (Advanced Surface Technology, Bleiswijk, The Netherlands) with a two component-nozzle, as described previously [7, 8]. The solvents for the coating consisted of 6.25 mM Ca(NO3)2 . 2H2O and 3.5 mM H3PO4 in butyl carbitol. The applied voltage was 6.3-6.4 kV, the flow rate 1 mL per hour per solvent, the deposition time 45 min, and the substrate temperature 350 degreesC. The nozzle-to-substrate distance was 20 mm. The deposited coatings had a thickness of 2 mum. After deposition, the substrates were subjected to an additional heat-treatment for 2 h at a temperature of 700 degreesC in air to crystallize the coating. After the heat-treatment, coatings were characterized by X-ray diffraction, Fourier-transform infrared, and scanning electron microscopy combined with electron dispersive spectroscopy, as crystalline carbonated hydroxyapatite, with a Ca/P ratio of 1.9-2.0 and a uniform porous surface morphology. Before use in the in vitro assays, all substrates were sterilized 15 min at 121 degreesC in an autoclave.
###end p 10
###begin title 11
Cell culture
###end title 11
###begin p 12
###xml 138 139 138 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 711 713 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 824 825 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 893 894 879 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 230 233 <span type="species:ncbi:10116">rat</span>
###xml 551 555 <span type="species:ncbi:9913">calf</span>
Rat bone marrow (RBM) cells were isolated and cultured to obtain osteoblast-like cells, using a method adapted from Maniatopoulos et al. [9]. For each individual run, RBM cells were obtained from both femora of one male Wistar WU rat (40-43 days old). Femora were washed four times in alpha-Minimal Essential Medium (alpha-MEM; Gibco BRL, Life Technologies B.V. Breda, The Netherlands) with 0.5 mg/mL gentamycin and 3 mug/mL fungizone. Epiphyses were cut off and diaphyses flushed out with 30 mL culture medium (alpha-MEM, supplemented with 10% fetal calf serum (FCS; Gibco), 50 mug/mL ascorbic acid (Sigma, Chemical Co., St. Louis, MO, USA), 50 mug/mL gentamycin, 10 mM Na-beta-glycerophosphate (Sigma), and 10-8 M dexamethasone (Sigma)). The flush-out of both femora was pooled and divided over three culture flasks (75 cm2). Cells were incubated in a humidified atmosphere of 95% air, 5% CO2 at 37 degreesC. After 7 days of primary culture osteoblast-like cells were detached using trypsin/EDTA (0.25% w/v trypsin/0.02% EDTA).
###end p 12
###begin title 13
Blocking with specific antibodies
###end title 13
###begin p 14
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 163 166 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 323 324 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
Integrin blocking was applied as described by McNally et al. [10]. Osteoblast-like cells were concentrated by centrifugation (350 g, 5 min), counted with a Coulter(R) Counter (Coulter Electronics Ltd., Luton, United Kingdom), concentrated by centrifugation (1,500 rpm, 5 min), and resuspended to a concentration of 1.5 x 106 cells in 1 mL PBS/BSA 0.5%. In the experimental groups, specific monoclonal anti-integrin-beta1 antibodies or anti-integrin-beta3 antibodies (Ha2/5 or 2C9.G2, respectively, both from BD Biosciences Pharmingen, NJ, USA) were added to the cells in a concentration of 50 mug/mL. The experimental groups were incubated at 4 degreesC for 30 min to allow antibodies to interact with the integrins on the osteoblast-like cells. The control group consisted of osteoblast-like cells without antibodies added, and was also incubated at 4 degreesC for 30 min.
###end p 14
###begin title 15
Cell seeding
###end title 15
###begin p 16
###xml 195 198 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 278 279 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
After 30 min of incubation with or without integrin antibodies, cells were concentrated by centrifugation (350 g, 5 min) and resuspended in culture medium. Cells were again counted with a Coulter(R) Counter, and seeded on the substrates at a concentration of 11,500 cells per cm2.
###end p 16
###begin title 17
Initial attachment and total cell amount
###end title 17
###begin p 18
###xml 409 412 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
After 30, 60, 120, and 240 min of incubation, and 1 and 3 days of culture, substrates were washed with PBS to remove all non-adherent cells, and placed in a new 24-well plate. Attached cells were released from the substrate with 0.5 mL trypsin/EDTA. After 5 min of incubation in 37 degreesC, 0.5 mL culture medium was added to block the enzymatic activity of the trypsin, and cells were counted with a Coulter(R) Counter. Cellular attachment was normalized to the values of the control group after 30 min of incubation on the relevant substrate (set at 100%). All substrates were routinely observed with light microscopy, to confirm the efficacy of the detachment procedure.
###end p 18
###begin title 19
Scanning electron microscopy (SEM)
###end title 19
###begin p 20
To observe changes in cell morphology, SEM was performed after 1 and 3 days of culture. Substrates were washed twice with PBS, and fixation was carried out for 5 min in 2% gluteraldehyde. Subsequently, substrates were washed with 0.1 M sodium-cacodylate buffer (pH 7.4), dehydrated in a graded series of ethanol, and dried in tetramethylsilane. The substrates were sputter-coated with gold and examined using a Jeol 6310 SEM (Tokyo, Japan).
###end p 20
###begin title 21
Real time quantitative RT-PCR 
###end title 21
###begin p 22
###xml 459 462 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 747 750 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 1062 1063 1023 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1164 1165 1121 1122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 1167 1185 1124 1142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T,gene of interest</sub>
###xml 1189 1196 1146 1153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T,GAPDH</sub>
###xml 1409 1410 1358 1359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 1417 1425 1362 1370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T,sample</sub>
###xml 1434 1443 1375 1384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T,control</sub>
###xml 1528 1541 1469 1474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;&#916;&#916;CT</sup>
###xml 1547 1549 1480 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1552 1559 1485 1492 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1559 1613 1492 1546 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Overview of the amplification primers used for QRT-PCR</p>
###xml 1559 1613 1492 1546 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Overview of the amplification primers used for QRT-PCR</p></caption>
###xml 1613 1613 1546 1546 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1613 1627 1546 1560 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Forward primer</th>
###xml 1627 1641 1560 1574 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Reverse primer</th>
###xml 1613 1641 1546 1574 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Forward primer</th><th align="left">Reverse primer</th></tr>
###xml 1613 1641 1546 1574 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Forward primer</th><th align="left">Reverse primer</th></tr></thead>
###xml 1641 1655 1574 1585 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">integrin-&#946;1</td>
###xml 1655 1679 1585 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;TGGTCAGCAGCGCATATCTG3&#8242;</td>
###xml 1679 1703 1609 1633 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;TGCATCAAAGCCACCTTCTG3&#8242;</td>
###xml 1641 1703 1574 1633 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">integrin-&#946;1</td><td align="left">5&#8242;TGGTCAGCAGCGCATATCTG3&#8242;</td><td align="left">5&#8242;TGCATCAAAGCCACCTTCTG3&#8242;</td></tr>
###xml 1703 1717 1633 1644 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">integrin-&#946;3</td>
###xml 1717 1742 1644 1669 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;CCACTGATGCCAAGACCCATA3&#8242;</td>
###xml 1742 1765 1669 1692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;AGACAATGCCTGCCAGCCT3&#8242;</td>
###xml 1703 1765 1633 1692 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">integrin-&#946;3</td><td align="left">5&#8242;CCACTGATGCCAAGACCCATA3&#8242;</td><td align="left">5&#8242;AGACAATGCCTGCCAGCCT3&#8242;</td></tr>
###xml 1765 1768 1692 1695 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ALP</td>
###xml 1768 1791 1695 1718 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;GCTTCACGGCATCCATGAG3&#8242;</td>
###xml 1791 1814 1718 1741 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;GAGGCATACGCCATGACGT3&#8242;</td>
###xml 1765 1814 1692 1741 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">ALP</td><td align="left">5&#8242;GCTTCACGGCATCCATGAG3&#8242;</td><td align="left">5&#8242;GAGGCATACGCCATGACGT3&#8242;</td></tr>
###xml 1814 1819 1741 1746 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GAPDH</td>
###xml 1819 1842 1746 1769 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;GCTTTGTGCAGTGCCAGCC3&#8242;</td>
###xml 1842 1867 1769 1794 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5&#8242;CACCGACCTTCACCATCTTGT3&#8242;</td>
###xml 1814 1867 1741 1794 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">GAPDH</td><td align="left">5&#8242;GCTTTGTGCAGTGCCAGCC3&#8242;</td><td align="left">5&#8242;CACCGACCTTCACCATCTTGT3&#8242;</td></tr>
###xml 1641 1867 1574 1794 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">integrin-&#946;1</td><td align="left">5&#8242;TGGTCAGCAGCGCATATCTG3&#8242;</td><td align="left">5&#8242;TGCATCAAAGCCACCTTCTG3&#8242;</td></tr><tr><td align="left">integrin-&#946;3</td><td align="left">5&#8242;CCACTGATGCCAAGACCCATA3&#8242;</td><td align="left">5&#8242;AGACAATGCCTGCCAGCCT3&#8242;</td></tr><tr><td align="left">ALP</td><td align="left">5&#8242;GCTTCACGGCATCCATGAG3&#8242;</td><td align="left">5&#8242;GAGGCATACGCCATGACGT3&#8242;</td></tr><tr><td align="left">GAPDH</td><td align="left">5&#8242;GCTTTGTGCAGTGCCAGCC3&#8242;</td><td align="left">5&#8242;CACCGACCTTCACCATCTTGT3&#8242;</td></tr></tbody>
###xml 1613 1867 1546 1794 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Forward primer</th><th align="left">Reverse primer</th></tr></thead><tbody><tr><td align="left">integrin-&#946;1</td><td align="left">5&#8242;TGGTCAGCAGCGCATATCTG3&#8242;</td><td align="left">5&#8242;TGCATCAAAGCCACCTTCTG3&#8242;</td></tr><tr><td align="left">integrin-&#946;3</td><td align="left">5&#8242;CCACTGATGCCAAGACCCATA3&#8242;</td><td align="left">5&#8242;AGACAATGCCTGCCAGCCT3&#8242;</td></tr><tr><td align="left">ALP</td><td align="left">5&#8242;GCTTCACGGCATCCATGAG3&#8242;</td><td align="left">5&#8242;GAGGCATACGCCATGACGT3&#8242;</td></tr><tr><td align="left">GAPDH</td><td align="left">5&#8242;GCTTTGTGCAGTGCCAGCC3&#8242;</td><td align="left">5&#8242;CACCGACCTTCACCATCTTGT3&#8242;</td></tr></tbody></table>
###xml 1552 1867 1485 1794 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="23">Overview of the amplification primers used for QRT-PCR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Forward primer</th><th align="left">Reverse primer</th></tr></thead><tbody><tr><td align="left">integrin-&#946;1</td><td align="left">5&#8242;TGGTCAGCAGCGCATATCTG3&#8242;</td><td align="left">5&#8242;TGCATCAAAGCCACCTTCTG3&#8242;</td></tr><tr><td align="left">integrin-&#946;3</td><td align="left">5&#8242;CCACTGATGCCAAGACCCATA3&#8242;</td><td align="left">5&#8242;AGACAATGCCTGCCAGCCT3&#8242;</td></tr><tr><td align="left">ALP</td><td align="left">5&#8242;GCTTCACGGCATCCATGAG3&#8242;</td><td align="left">5&#8242;GAGGCATACGCCATGACGT3&#8242;</td></tr><tr><td align="left">GAPDH</td><td align="left">5&#8242;GCTTTGTGCAGTGCCAGCC3&#8242;</td><td align="left">5&#8242;CACCGACCTTCACCATCTTGT3&#8242;</td></tr></tbody></table></table-wrap>
The gene expression for integrins beta1 and beta3, and alkaline phosphatase was also examined. After 1 and 3 days of culture, RNA was isolated from the cells using a RNA isolation kit (Qiagen, Hilden, Germany). After the isolation of the RNA, the reverse transcriptase (RT)-reaction was performed. The cDNA from the RT-reaction was used as a template in the polymerase chain reaction (PCR). To perform quantitative PCR, 4.5 muL RNase-free water, 12.5 muL SYBR(R) Green MasterMix (Eurogentec, Liege, Belgium), 5 muL cDNA, 1.5 muL Reverse Primer and 1.5 muL Forward Primer were added to a QRT-PCR-96-well plate. This plate was sealed, and the Q-PCR-run was performed with the MyiQ Single-Color Real-Time Detection System for quantification with SYBR(R) Green and melting curve analysis (Biorad, Richmond, CA, USA). DNA was PCR-amplified under the following conditions: 2 min at 50 degreesC and 10 min at 95 degreesC, followed by 40 cycles of 15 s at 95 degreesC and 1 min at 60 degreesC, with data collection in the last 30 s. The used primers are listed in Table 2. The reference household-gene used to normalize the amount of mRNA in the cultures was GAPDH (DeltaCT=CT,gene of interest - CT,GAPDH (1)). Gene expression was measured relative to the gene expression of cultures on the relevant substrates (either CaP-coated or non coated Ti) that had not received antibodies, after day 1 of culture (DeltaDeltaCT=DeltaCT,sample - DeltaCT,control (2)). The fold change in gene expression relative to the control was calculated by 2-DeltaDeltaCT (3) [11]. Table 2Overview of the amplification primers used for QRT-PCRForward primerReverse primerintegrin-beta15'TGGTCAGCAGCGCATATCTG3'5'TGCATCAAAGCCACCTTCTG3'integrin-beta35'CCACTGATGCCAAGACCCATA3'5'AGACAATGCCTGCCAGCCT3'ALP5'GCTTCACGGCATCCATGAG3'5'GAGGCATACGCCATGACGT3'GAPDH5'GCTTTGTGCAGTGCCAGCC3'5'CACCGACCTTCACCATCTTGT3'
###end p 22
###begin p 23
Overview of the amplification primers used for QRT-PCR
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
All assays were performed in triplicate. Statistical analysis for initial attachment and total cell amount was performed using a two-way ANOVA. As post-hoc comparison, a Tukey test was performed. A probability (P) value less than 0.05 was considered statistically significant. The experiments was replicated multiple times, but only the two independent experiments which were most representative for the results obtained overall are presented in the current investigation, and hereafter termed 'run 1' and 'run 2'.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
Initial attachment and total cell amount
###end title 27
###begin title 28
CaP-coated substrates
###end title 28
###begin p 29
###xml 147 149 142 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 279 281 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 295 296 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 466 468 451 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 580 581 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 604 605 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 622 623 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 645 646 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 661 662 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 669 675 651 657 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 714 715 696 697 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 722 723 704 705 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 799 800 781 782 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 807 808 789 790 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 975 977 954 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#&#160;</sup>
###xml 675 1121 657 1097 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Cellular attachment in the first run. (<bold>A</bold>) and (<bold>B</bold>) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (<bold>C</bold>) and (<bold>D</bold>) non-coated Ti. *&#160;indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-&#946;1 antibodies. <sup>#&#160;</sup>indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-&#946;3 antibodies</p>
###xml 675 1121 657 1097 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Cellular attachment in the first run. (<bold>A</bold>) and (<bold>B</bold>) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (<bold>C</bold>) and (<bold>D</bold>) non-coated Ti. *&#160;indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-&#946;1 antibodies. <sup>#&#160;</sup>indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-&#946;3 antibodies</p></caption>
###xml 1121 1121 1097 1097 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10856_2007_166_Fig1_HTML" id="MO1"/>
###xml 669 1121 651 1097 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="30">Cellular attachment in the first run. (<bold>A</bold>) and (<bold>B</bold>) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (<bold>C</bold>) and (<bold>D</bold>) non-coated Ti. *&#160;indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-&#946;1 antibodies. <sup>#&#160;</sup>indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-&#946;3 antibodies</p></caption><graphic position="anchor" xlink:href="10856_2007_166_Fig1_HTML" id="MO1"/></fig>
###xml 1121 1127 1097 1103 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1167 1168 1143 1144 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1175 1176 1151 1152 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1252 1253 1228 1229 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1260 1261 1236 1237 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 1428 1429 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 1127 1574 1103 1544 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Cellular attachment in the second run. (<bold>A</bold>) and (<bold>B</bold>) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (<bold>C</bold>) and (<bold>D</bold>) non-coated Ti. *&#160;indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-&#946;1 antibodies. <sup>#</sup>&#160;indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-&#946;3 antibodies</p>
###xml 1127 1574 1103 1544 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Cellular attachment in the second run. (<bold>A</bold>) and (<bold>B</bold>) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (<bold>C</bold>) and (<bold>D</bold>) non-coated Ti. *&#160;indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-&#946;1 antibodies. <sup>#</sup>&#160;indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-&#946;3 antibodies</p></caption>
###xml 1574 1574 1544 1544 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10856_2007_166_Fig2_HTML" id="MO2"/>
###xml 1121 1574 1097 1544 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="31">Cellular attachment in the second run. (<bold>A</bold>) and (<bold>B</bold>) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (<bold>C</bold>) and (<bold>D</bold>) non-coated Ti. *&#160;indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-&#946;1 antibodies. <sup>#</sup>&#160;indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-&#946;3 antibodies</p></caption><graphic position="anchor" xlink:href="10856_2007_166_Fig2_HTML" id="MO2"/></fig>
In the first run, the initial cellular attachment was decreased after 30 min for +/-30% after a pre-treatment with anti-integrin-beta1 antibodies (P < 0.05). With a pre-treatment of anti-integrin-beta3 antibodies, initial attachment was decreased for +/-40% after 30 and 60 min (P < 0.01) (Fig. 1A, B). In the second run, a pre-treatment with anti-integrin-beta1 antibodies gave a reduction of +/-20-30% in cellular attachment after 60 and 240 min, and after 1 day (P < 0.05). A pre-treatment with anti-integrin-beta3 antibodies decreased cellular attachment for 40-50% after 30 (P < 0.01), 60, 240 min (P < 0.05), 1 day (P < 0.01), and 3 days (P < 0.05) (Fig. 2A, B). Fig. 1Cellular attachment in the first run. (A) and (B) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (C) and (D) non-coated Ti. * indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-beta1 antibodies. # indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-beta3 antibodiesFig. 2Cellular attachment in the second run. (A) and (B) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (C) and (D) non-coated Ti. * indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-beta1 antibodies. # indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-beta3 antibodies
###end p 29
###begin p 30
###xml 39 40 39 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 47 48 47 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 124 125 124 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 132 133 132 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 300 302 297 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#&#160;</sup>
Cellular attachment in the first run. (A) and (B) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (C) and (D) non-coated Ti. * indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-beta1 antibodies. # indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-beta3 antibodies
###end p 30
###begin p 31
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 48 49 48 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 133 134 133 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 301 302 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
Cellular attachment in the second run. (A) and (B) CaP-coated substrates derived with Electrostatic Spray Deposition (ESD); (C) and (D) non-coated Ti. * indicates a significant difference between the control group and the experimental group with the pre-treatment with anti-integrin-beta1 antibodies. # indicates a significant difference between the control group and the experimental group that was pre-treated with anti-integrin-beta3 antibodies
###end p 31
###begin title 32
Non coated Ti substrates
###end title 32
###begin p 33
###xml 405 406 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 685 686 671 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 701 702 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
In general, integrin blocking had a less effect on the bare Ti substrates. In the first run, no differences were observed in initial cellular attachment or cell number with a pre-treatment of anti-integrin-beta1 or anti-integrin-beta3 antibodies, although the means are quite different. Possibly, if the error were smaller, it would emerge that the function blocking antibodies were indeed effective (Fig.1C, D). However, also in the second run, no differences in initial attachment were observed with the pre-treatment of anti-integrin-beta1 antibodies. However, with a pre-treatment of anti-integrin-beta3 antibodies, a decrease of +/-30% in attachment was seen after 30 and 60 min (P < 0.05) (Fig. 2C, D).
###end p 33
###begin title 34
SEM
###end title 34
###begin title 35
CaP-coated substrates
###end title 35
###begin p 36
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 431 432 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 475 476 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 549 555 543 549 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 625 626 619 620 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 628 629 622 623 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 635 636 629 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 666 667 660 661 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 669 670 663 664 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 676 677 670 671 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 784 785 778 779 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 790 791 784 785 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 887 888 878 879 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 893 894 884 885 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 932 933 920 921 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 938 939 926 927 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 555 940 549 928 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Scanning electron micrographs of osteoblast-like cells on CaP-coated (<bold>A</bold>, <bold>B</bold>, and <bold>C</bold>) substrates, and non-coated (<bold>D</bold>, <bold>E</bold>, and <bold>F</bold>) Ti substrates after 1&#160;day of culture. There were no morphological differences between the control group (<bold>A</bold> and <bold>D</bold>), or the experimental groups that were either pre-treated with anti-integrin-&#946;1 antibodies (<bold>B</bold> and <bold>E</bold>), or anti-integrin-&#946;3 antibodies (<bold>C</bold> and <bold>F</bold>)</p>
###xml 555 940 549 928 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Scanning electron micrographs of osteoblast-like cells on CaP-coated (<bold>A</bold>, <bold>B</bold>, and <bold>C</bold>) substrates, and non-coated (<bold>D</bold>, <bold>E</bold>, and <bold>F</bold>) Ti substrates after 1&#160;day of culture. There were no morphological differences between the control group (<bold>A</bold> and <bold>D</bold>), or the experimental groups that were either pre-treated with anti-integrin-&#946;1 antibodies (<bold>B</bold> and <bold>E</bold>), or anti-integrin-&#946;3 antibodies (<bold>C</bold> and <bold>F</bold>)</p></caption>
###xml 940 940 928 928 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10856_2007_166_Fig3_HTML" id="MO3"/>
###xml 549 940 543 928 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="37">Scanning electron micrographs of osteoblast-like cells on CaP-coated (<bold>A</bold>, <bold>B</bold>, and <bold>C</bold>) substrates, and non-coated (<bold>D</bold>, <bold>E</bold>, and <bold>F</bold>) Ti substrates after 1&#160;day of culture. There were no morphological differences between the control group (<bold>A</bold> and <bold>D</bold>), or the experimental groups that were either pre-treated with anti-integrin-&#946;1 antibodies (<bold>B</bold> and <bold>E</bold>), or anti-integrin-&#946;3 antibodies (<bold>C</bold> and <bold>F</bold>)</p></caption><graphic position="anchor" xlink:href="10856_2007_166_Fig3_HTML" id="MO3"/></fig>
In both runs, osteoblast-like cells on CaP-coated substrates had attached and spread over the substrate surface after 1 day of culture (Fig. 3A). Cells exhibited a typical phenotype for osteoblasts in culture, i.e. a flat monolayer with multiple cell extensions, and frequent cell-to-cell contact. After 3 days of culture, cells were more elongated and more numerous. Pre-treatment with either anti-integrin-beta1 antibodies (Fig. 3B) or anti-integrin-beta3 antibodies (Fig. 3C) did not noticeably change cellular morphology upon visual inspection. Fig. 3Scanning electron micrographs of osteoblast-like cells on CaP-coated (A, B, and C) substrates, and non-coated (D, E, and F) Ti substrates after 1 day of culture. There were no morphological differences between the control group (A and D), or the experimental groups that were either pre-treated with anti-integrin-beta1 antibodies (B and E), or anti-integrin-beta3 antibodies (C and F)
###end p 36
###begin p 37
###xml 70 71 70 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 73 74 73 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 80 81 80 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 111 112 111 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 114 115 114 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 121 122 121 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
###xml 229 230 229 230 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 235 236 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 332 333 329 330 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 338 339 335 336 <bold xmlns:xlink="http://www.w3.org/1999/xlink">E</bold>
###xml 377 378 371 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 383 384 377 378 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
Scanning electron micrographs of osteoblast-like cells on CaP-coated (A, B, and C) substrates, and non-coated (D, E, and F) Ti substrates after 1 day of culture. There were no morphological differences between the control group (A and D), or the experimental groups that were either pre-treated with anti-integrin-beta1 antibodies (B and E), or anti-integrin-beta3 antibodies (C and F)
###end p 37
###begin title 38
Non coated Ti substrates
###end title 38
###begin p 39
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
On non coated Ti-substrates, osteoblast-like cells were also stretched out over the surface after 1 day of culture (Fig. 3D). After 3 days, more cells were present, which were well spread. After pre-treatment with both specific antibodies (Fig. 3E, F), no changes in morphology were observed, after both 1 and 3 days of culture.
###end p 39
###begin title 40
Real time quantitative RT-PCR
###end title 40
###begin p 41
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 228 235 228 235 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 235 433 235 430 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42">mRNA expression. Listed are the normalized changes (percentages) in mRNA expression of integrins-&#946;1 and 3, and ALP, relative to the control group after 1&#160;day of culture on both types of substrate</p>
###xml 235 433 235 430 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42">mRNA expression. Listed are the normalized changes (percentages) in mRNA expression of integrins-&#946;1 and 3, and ALP, relative to the control group after 1&#160;day of culture on both types of substrate</p></caption>
###xml 433 480 430 474 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">MRNA expression of integrin-&#946;1 (percentages)</th>
###xml 433 480 430 474 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="6">MRNA expression of integrin-&#946;1 (percentages)</th></tr>
###xml 480 480 474 474 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 480 480 474 474 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 480 485 474 479 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">run 1</th>
###xml 485 490 479 484 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">run 2</th>
###xml 480 490 474 484 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left"/><th align="left" colspan="2">run 1</th><th align="left" colspan="2">run 2</th></tr>
###xml 490 490 484 484 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 490 490 484 484 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 490 495 484 489 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">day 1</th>
###xml 495 500 489 494 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">day 3</th>
###xml 500 505 494 499 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">day 1</th>
###xml 505 510 499 504 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">day 3</th>
###xml 490 510 484 504 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left"/><th align="left">day 1</th><th align="left">day 3</th><th align="left">day 1</th><th align="left">day 3</th></tr>
###xml 433 510 430 504 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" colspan="6">MRNA expression of integrin-&#946;1 (percentages)</th></tr><tr><th align="left"/><th align="left"/><th align="left" colspan="2">run 1</th><th align="left" colspan="2">run 2</th></tr><tr><th align="left"/><th align="left"/><th align="left">day 1</th><th align="left">day 3</th><th align="left">day 1</th><th align="left">day 3</th></tr></thead>
###xml 510 520 504 514 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">CaP-coated</td>
###xml 520 527 514 521 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">control</td>
###xml 527 530 521 524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 530 533 524 527 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">134</td>
###xml 533 536 527 530 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 536 539 530 533 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">492</td>
###xml 510 539 504 533 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">134</td><td char="." align="char">100</td><td char="." align="char">492</td></tr>
###xml 539 558 533 549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;1</td>
###xml 558 561 549 552 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">570</td>
###xml 561 564 552 555 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">220</td>
###xml 564 566 555 557 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">84</td>
###xml 566 569 557 560 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">513</td>
###xml 539 569 533 560 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;1</td><td char="." align="char">570</td><td char="." align="char">220</td><td char="." align="char">84</td><td char="." align="char">513</td></tr>
###xml 569 588 560 576 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;3</td>
###xml 588 591 576 579 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">453</td>
###xml 591 594 579 582 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">196</td>
###xml 594 597 582 585 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">107</td>
###xml 597 600 585 588 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">566</td>
###xml 569 600 560 588 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;3</td><td char="." align="char">453</td><td char="." align="char">196</td><td char="." align="char">107</td><td char="." align="char">566</td></tr>
###xml 600 602 588 590 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Ti</td>
###xml 602 609 590 597 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">control</td>
###xml 609 612 597 600 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 612 615 600 603 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">243</td>
###xml 615 618 603 606 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 618 621 606 609 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">392</td>
###xml 600 621 588 609 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">243</td><td char="." align="char">100</td><td char="." align="char">392</td></tr>
###xml 621 640 609 625 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;1</td>
###xml 640 643 625 628 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">222</td>
###xml 643 646 628 631 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">554</td>
###xml 646 649 631 634 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">154</td>
###xml 649 652 634 637 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">636</td>
###xml 621 652 609 637 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;1</td><td char="." align="char">222</td><td char="." align="char">554</td><td char="." align="char">154</td><td char="." align="char">636</td></tr>
###xml 652 671 637 653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;3</td>
###xml 671 674 653 656 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">320</td>
###xml 674 677 656 659 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">426</td>
###xml 677 680 659 662 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">145</td>
###xml 680 683 662 665 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">794</td>
###xml 652 683 637 665 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;3</td><td char="." align="char">320</td><td char="." align="char">426</td><td char="." align="char">145</td><td char="." align="char">794</td></tr>
###xml 683 730 665 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">mRNA expression of integrin-&#946;3 (percentages)</td>
###xml 683 730 665 709 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">mRNA expression of integrin-&#946;3 (percentages)</td></tr>
###xml 730 740 709 719 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">CaP-coated</td>
###xml 740 747 719 726 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">control</td>
###xml 747 750 726 729 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 750 752 729 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19</td>
###xml 752 755 731 734 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 755 757 734 736 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14</td>
###xml 730 757 709 736 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">19</td><td char="." align="char">100</td><td char="." align="char">14</td></tr>
###xml 757 776 736 752 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;1</td>
###xml 776 778 752 754 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71</td>
###xml 778 779 754 755 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 779 781 755 757 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50</td>
###xml 781 783 757 759 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 757 783 736 759 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;1</td><td char="." align="char">71</td><td char="." align="char">8</td><td char="." align="char">50</td><td char="." align="char">21</td></tr>
###xml 783 802 759 775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anti-integrin-&#946;3</td>
###xml 802 804 775 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">41</td>
###xml 804 805 777 778 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 805 807 778 780 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 807 809 780 782 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 783 809 759 782 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">41</td><td char="." align="char">9</td><td char="." align="char">30</td><td char="." align="char">15</td></tr>
###xml 809 811 782 784 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Ti</td>
###xml 811 818 784 791 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">control</td>
###xml 818 821 791 794 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 821 823 794 796 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">39</td>
###xml 823 826 796 799 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 826 829 799 802 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">140</td>
###xml 809 829 782 802 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">39</td><td char="." align="char">100</td><td char="." align="char">140</td></tr>
###xml 829 848 802 818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;1</td>
###xml 848 851 818 821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">149</td>
###xml 851 853 821 823 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 853 856 823 826 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">817</td>
###xml 856 858 826 828 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">91</td>
###xml 829 858 802 828 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;1</td><td char="." align="char">149</td><td char="." align="char">12</td><td char="." align="char">817</td><td char="." align="char">91</td></tr>
###xml 858 877 828 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">anti-integrin-&#946;3</td>
###xml 877 879 844 846 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48</td>
###xml 879 881 846 848 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 881 884 848 851 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">673</td>
###xml 884 887 851 854 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">701</td>
###xml 858 887 828 854 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">anti-integrin-&#946;3</td><td char="." align="char">48</td><td char="." align="char">10</td><td char="." align="char">673</td><td char="." align="char">701</td></tr>
###xml 887 923 854 890 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="6">mRNA expression of ALP (percentages)</td>
###xml 887 923 854 890 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="6">mRNA expression of ALP (percentages)</td></tr>
###xml 923 933 890 900 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">CaP-coated</td>
###xml 933 940 900 907 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">control</td>
###xml 940 943 907 910 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 943 945 910 912 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">49</td>
###xml 945 948 912 915 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 948 950 915 917 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50</td>
###xml 923 950 890 917 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">49</td><td char="." align="char">100</td><td char="." align="char">50</td></tr>
###xml 950 969 917 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anti-integrin-&#946;1</td>
###xml 969 971 933 935 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">84</td>
###xml 971 972 935 936 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 972 974 936 938 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">92</td>
###xml 974 976 938 940 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 950 976 917 940 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">84</td><td char="." align="char">4</td><td char="." align="char">92</td><td char="." align="char">33</td></tr>
###xml 976 995 940 956 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anti-integrin-&#946;3</td>
###xml 995 997 956 958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">73</td>
###xml 997 998 958 959 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 998 1000 959 961 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1000 1002 961 963 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">31</td>
###xml 976 1002 940 963 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">73</td><td char="." align="char">1</td><td char="." align="char">17</td><td char="." align="char">31</td></tr>
###xml 1002 1004 963 965 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Ti</td>
###xml 1004 1011 965 972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">control</td>
###xml 1011 1014 972 975 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 1014 1016 975 977 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50</td>
###xml 1016 1019 977 980 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 1019 1021 980 982 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 1002 1021 963 982 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">50</td><td char="." align="char">100</td><td char="." align="char">20</td></tr>
###xml 1021 1040 982 998 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anti-integrin-&#946;1</td>
###xml 1040 1043 998 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">127</td>
###xml 1043 1044 1001 1002 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1044 1046 1002 1004 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">58</td>
###xml 1046 1047 1004 1005 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1021 1047 982 1005 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">127</td><td char="." align="char">4</td><td char="." align="char">58</td><td char="." align="char">4</td></tr>
###xml 1047 1066 1005 1021 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Anti-integrin-&#946;3</td>
###xml 1066 1068 1021 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">86</td>
###xml 1068 1070 1023 1025 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">39</td>
###xml 1070 1071 1025 1026 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1071 1072 1026 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1047 1072 1005 1027 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">86</td><td char="." align="char">39</td><td char="." align="char">2</td><td char="." align="char">5</td></tr>
###xml 510 1072 504 1027 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">134</td><td char="." align="char">100</td><td char="." align="char">492</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">570</td><td char="." align="char">220</td><td char="." align="char">84</td><td char="." align="char">513</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">453</td><td char="." align="char">196</td><td char="." align="char">107</td><td char="." align="char">566</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">243</td><td char="." align="char">100</td><td char="." align="char">392</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">222</td><td char="." align="char">554</td><td char="." align="char">154</td><td char="." align="char">636</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">320</td><td char="." align="char">426</td><td char="." align="char">145</td><td char="." align="char">794</td></tr><tr><td align="left" colspan="6">mRNA expression of integrin-&#946;3 (percentages)</td></tr><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">19</td><td char="." align="char">100</td><td char="." align="char">14</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">71</td><td char="." align="char">8</td><td char="." align="char">50</td><td char="." align="char">21</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">41</td><td char="." align="char">9</td><td char="." align="char">30</td><td char="." align="char">15</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">39</td><td char="." align="char">100</td><td char="." align="char">140</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">149</td><td char="." align="char">12</td><td char="." align="char">817</td><td char="." align="char">91</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">48</td><td char="." align="char">10</td><td char="." align="char">673</td><td char="." align="char">701</td></tr><tr><td align="left" colspan="6">mRNA expression of ALP (percentages)</td></tr><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">49</td><td char="." align="char">100</td><td char="." align="char">50</td></tr><tr><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">84</td><td char="." align="char">4</td><td char="." align="char">92</td><td char="." align="char">33</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">73</td><td char="." align="char">1</td><td char="." align="char">17</td><td char="." align="char">31</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">50</td><td char="." align="char">100</td><td char="." align="char">20</td></tr><tr><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">127</td><td char="." align="char">4</td><td char="." align="char">58</td><td char="." align="char">4</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">86</td><td char="." align="char">39</td><td char="." align="char">2</td><td char="." align="char">5</td></tr></tbody>
###xml 433 1072 430 1027 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6">MRNA expression of integrin-&#946;1 (percentages)</th></tr><tr><th align="left"/><th align="left"/><th align="left" colspan="2">run 1</th><th align="left" colspan="2">run 2</th></tr><tr><th align="left"/><th align="left"/><th align="left">day 1</th><th align="left">day 3</th><th align="left">day 1</th><th align="left">day 3</th></tr></thead><tbody><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">134</td><td char="." align="char">100</td><td char="." align="char">492</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">570</td><td char="." align="char">220</td><td char="." align="char">84</td><td char="." align="char">513</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">453</td><td char="." align="char">196</td><td char="." align="char">107</td><td char="." align="char">566</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">243</td><td char="." align="char">100</td><td char="." align="char">392</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">222</td><td char="." align="char">554</td><td char="." align="char">154</td><td char="." align="char">636</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">320</td><td char="." align="char">426</td><td char="." align="char">145</td><td char="." align="char">794</td></tr><tr><td align="left" colspan="6">mRNA expression of integrin-&#946;3 (percentages)</td></tr><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">19</td><td char="." align="char">100</td><td char="." align="char">14</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">71</td><td char="." align="char">8</td><td char="." align="char">50</td><td char="." align="char">21</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">41</td><td char="." align="char">9</td><td char="." align="char">30</td><td char="." align="char">15</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">39</td><td char="." align="char">100</td><td char="." align="char">140</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">149</td><td char="." align="char">12</td><td char="." align="char">817</td><td char="." align="char">91</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">48</td><td char="." align="char">10</td><td char="." align="char">673</td><td char="." align="char">701</td></tr><tr><td align="left" colspan="6">mRNA expression of ALP (percentages)</td></tr><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">49</td><td char="." align="char">100</td><td char="." align="char">50</td></tr><tr><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">84</td><td char="." align="char">4</td><td char="." align="char">92</td><td char="." align="char">33</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">73</td><td char="." align="char">1</td><td char="." align="char">17</td><td char="." align="char">31</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">50</td><td char="." align="char">100</td><td char="." align="char">20</td></tr><tr><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">127</td><td char="." align="char">4</td><td char="." align="char">58</td><td char="." align="char">4</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">86</td><td char="." align="char">39</td><td char="." align="char">2</td><td char="." align="char">5</td></tr></tbody></table>
###xml 228 1072 228 1027 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="42">mRNA expression. Listed are the normalized changes (percentages) in mRNA expression of integrins-&#946;1 and 3, and ALP, relative to the control group after 1&#160;day of culture on both types of substrate</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="6">MRNA expression of integrin-&#946;1 (percentages)</th></tr><tr><th align="left"/><th align="left"/><th align="left" colspan="2">run 1</th><th align="left" colspan="2">run 2</th></tr><tr><th align="left"/><th align="left"/><th align="left">day 1</th><th align="left">day 3</th><th align="left">day 1</th><th align="left">day 3</th></tr></thead><tbody><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">134</td><td char="." align="char">100</td><td char="." align="char">492</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">570</td><td char="." align="char">220</td><td char="." align="char">84</td><td char="." align="char">513</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">453</td><td char="." align="char">196</td><td char="." align="char">107</td><td char="." align="char">566</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">243</td><td char="." align="char">100</td><td char="." align="char">392</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">222</td><td char="." align="char">554</td><td char="." align="char">154</td><td char="." align="char">636</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">320</td><td char="." align="char">426</td><td char="." align="char">145</td><td char="." align="char">794</td></tr><tr><td align="left" colspan="6">mRNA expression of integrin-&#946;3 (percentages)</td></tr><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">19</td><td char="." align="char">100</td><td char="." align="char">14</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">71</td><td char="." align="char">8</td><td char="." align="char">50</td><td char="." align="char">21</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">41</td><td char="." align="char">9</td><td char="." align="char">30</td><td char="." align="char">15</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">39</td><td char="." align="char">100</td><td char="." align="char">140</td></tr><tr><td align="left">anti-integrin-&#946;1</td><td char="." align="char">149</td><td char="." align="char">12</td><td char="." align="char">817</td><td char="." align="char">91</td></tr><tr><td align="left">anti-integrin-&#946;3</td><td char="." align="char">48</td><td char="." align="char">10</td><td char="." align="char">673</td><td char="." align="char">701</td></tr><tr><td align="left" colspan="6">mRNA expression of ALP (percentages)</td></tr><tr><td align="left" rowspan="3">CaP-coated</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">49</td><td char="." align="char">100</td><td char="." align="char">50</td></tr><tr><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">84</td><td char="." align="char">4</td><td char="." align="char">92</td><td char="." align="char">33</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">73</td><td char="." align="char">1</td><td char="." align="char">17</td><td char="." align="char">31</td></tr><tr><td align="left" rowspan="3">Ti</td><td align="left">control</td><td char="." align="char">100</td><td char="." align="char">50</td><td char="." align="char">100</td><td char="." align="char">20</td></tr><tr><td align="left">Anti-integrin-&#946;1</td><td char="." align="char">127</td><td char="." align="char">4</td><td char="." align="char">58</td><td char="." align="char">4</td></tr><tr><td align="left">Anti-integrin-&#946;3</td><td char="." align="char">86</td><td char="." align="char">39</td><td char="." align="char">2</td><td char="." align="char">5</td></tr></tbody></table></table-wrap>
Real time quantitative RT-PCR (QRT-PCR) was performed to determine the gene expression relative to the control group (cell culture without a pre-treatment with integrin antibodies). The results of QRT-PCR are listed in Table 3. Table 3mRNA expression. Listed are the normalized changes (percentages) in mRNA expression of integrins-beta1 and 3, and ALP, relative to the control group after 1 day of culture on both types of substrateMRNA expression of integrin-beta1 (percentages)run 1run 2day 1day 3day 1day 3CaP-coatedcontrol100134100492anti-integrin-beta157022084513anti-integrin-beta3453196107566Ticontrol100243100392anti-integrin-beta1222554154636anti-integrin-beta3320426145794mRNA expression of integrin-beta3 (percentages)CaP-coatedcontrol1001910014anti-integrin-beta17185021Anti-integrin-beta34193015Ticontrol10039100140anti-integrin-beta11491281791anti-integrin-beta34810673701mRNA expression of ALP (percentages)CaP-coatedcontrol1004910050Anti-integrin-beta18449233Anti-integrin-beta37311731Ticontrol1005010020Anti-integrin-beta11274584Anti-integrin-beta3863925
###end p 41
###begin p 42
mRNA expression. Listed are the normalized changes (percentages) in mRNA expression of integrins-beta1 and 3, and ALP, relative to the control group after 1 day of culture on both types of substrate
###end p 42
###begin title 43
mRNA expression of integrin-beta1 on CaP-coated substrates
###end title 43
###begin p 44
###xml 301 302 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
In the control groups, mRNA expression of integrin-beta1 increased from day 1 to day 3. In the first run, after a pre-treatment with either anti-integrin-beta1 or anti-integrin-beta3 antibodies, mRNA of integrin-beta1 was increased, compared to the control group, after 1 and 3 days of culture (Table 3). In the second run, a similar increase was seen, which however was delayed until day 3 for both experimental groups.
###end p 44
###begin title 45
mRNA expression of integrin-beta1 on non coated Ti substrates
###end title 45
###begin p 46
###xml 345 346 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
Also on the bare Ti, the mRNA expression of integrin-beta1 was increased in the control group after 3 days of culture. In the first run, a pre-treatment with anti-integrin-beta1 antibodies increased the mRNA expression of integrin-beta1. A pre-treatment with anti-integrin-beta3 antibodies also gave an increase in mRNA of integrin-beta1 (Table 3). In the second run similar trends were seen. However, now the increase was delayed, either after a pre-treatment with anti-integrin-beta1 or anti-integrin-beta3 antibodies.
###end p 46
###begin title 47
mRNA expression of integrin-beta3 on CaP-coated substrates
###end title 47
###begin p 48
###xml 326 327 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
Opposite to the expression of integrin-beta1, the mRNA expression of integrin-beta3 was decreased on the control sample after 3 days of culture. In both performed runs, a pre-treatment with either anti-integrin-beta1 or anti-integrin-beta3 antibodies decreased the mRNA of integrin-beta3, after 1 and 3 days of culture (Table 3).
###end p 48
###begin title 49
mRNA expression of integrin-beta3 on non coated Ti substrates
###end title 49
###begin p 50
###xml 783 784 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
In the first run, the control group had a decreased mRNA expression of integrin-beta3 after 3 days of culture. After a pre-treatment of the cells with anti-integrin-beta1 antibodies, mRNA of integrin-beta3 was increased after 1 day, but decreased after 3 days of culture. A pre-treatment with anti-integrin-beta3 antibodies decreased mRNA of integrin-beta3 after 1 and 3 days of culture. In the second run, mRNA of integrin-beta3 in the control group was increased from day 1 to day 3. A pre-treatment with anti-integrin-beta1 antibodies increased mRNA of integrin-beta3 after 1 day of culture, and decreased after 3 days of culture. After a pre-treatment with anti-integrin-beta3 antibodies, mRNA expression of integrin-beta3 was increased after both 1 and 3 days of culture (Table 3).
###end p 50
###begin title 51
mRNA expression of ALP on CaP-coated substrates
###end title 51
###begin p 52
###xml 237 238 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
The mRNA expression of ALP in the control group decreased from day 1 to day 3. A pre-treatment of the cells with either anti-integrin-beta1 or anti-integrin-beta3 antibodies decreased the mRNA of ALP after 1 and 3 days of culture (Table 3).
###end p 52
###begin title 53
mRNA expression of ALP on non coated Ti substrates
###end title 53
###begin p 54
###xml 280 281 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
In the control group, mRNA expression of ALP was decreased from day 1 to day 3. A pre-treatment with anti-integrin-beta1 antibodies decreased the mRNA expression of ALP. A decrease in mRNA of ALP was also observed after a pre-treatment with anti-integrin-beta3 antibodies (Table  3).
###end p 54
###begin title 55
Discussion and conclusion
###end title 55
###begin p 56
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
Integrins are involved in the attachment of cells to the proteins that are adsorbed to the surface of a substrate or implant [3, 4]. Furthermore, they are relevant for the signaling of the ECM with the cell and of the cell with the ECM, influencing cellular behavior [5, 6]. This study examined the effects of blocking integrin-beta1 or integrin-beta3 with specific monoclonal antibodies on the cellular behavior of primary osteoblast-like cells cultured on an ESD-derived CaP coating, or on non coated Ti substrates. The results showed an affected initial attachment, and an altered mRNA expression of integrin-beta1, integrin-beta3, and ALP, when the function of integrin-beta1 or integrin-beta3 was inhibited.
###end p 56
###begin p 57
###xml 259 261 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 263 265 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 267 269 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 561 563 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
First, general remarks have to be made regarding the method used to block the integrins. Osteoblast-like cells were pre-treated with monoclonal antibodies in PBS/BSA 0.5% and incubated at 4 degreesC for 30 min, as previously employed by multiple researchers [10, 12, 13]. No serum was added to the cell suspension while the antibodies were incubated to avoid competitive binding of the antibodies with serum proteins. In contrast, another study describes the addition of antibodies to the cells, in complete culture medium after seeding them on the substrates [14]. Using this latter method, the antibodies only influenced cell signaling, as cells had already adhered. In the present study, the antibodies were added in suspension before cell seeding on the substrates. Using this method, all integrins on the surface were blocked, affecting the function of integrins in both attachment and cell signaling. Moreover, in the current study blocking antibodies were used at a concentration of 50 mug/mL, which is very likely to be a saturating concentration. However, at high antibody concentrations, even nonspecific IgGs could possibly have had some inhibitory effect on cell adhesion. For future experiments, isotype-matched nonspecific IgGs should be studied also to control for nonspecific effects. However, such future studies on a comparative analysis of the functions of integrin-beta1 versus integrin-beta3 could also concentrate on other methods besides blocking the function with antibodies. General disadvantages of antibody blocking procedures are that the binding affinities, as well as the expression level can differ between the two integrins. More conclusive studies could be performed to compare the functions of integrin-beta1 and integrin-beta3, like using knock-out animals or siRNA techniques. Such studies then should encompass not only transcription (as studied here) but be complemented by experiments verifying that integrin protein expression changes (e.g. Western blots or flow cytometry). Integrins are highly regulated at many levels; transcriptional, translational, and post-translational. It is well established that changes in integrin mRNA levels do not always translate to greater integrin protein expression and/or activity.
###end p 57
###begin p 58
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
Concerning the overall study results, it is evident that differences exist between the two performed runs. Several explanations can be given for these observations. First, it is known that integrin expression is a very dynamic process [15-18]. Furthermore, the proteins adsorbed to the surface are not immobile, and the cell itself produces ECM proteins, which influence the integrin expression. Finally, there might be variability between the heterogeneous cell populations of both runs. However, this in vitro-research was designed to determine the importance of integrins in the behavior of primary osteoblast-like cells. Despite the differences between the two runs, the same tendency was observed, confirming that the results are reliable.
###end p 58
###begin p 59
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
CaP-coated and plain Ti materials are both commonly used for the production of dental implants. However, studies have shown a beneficial osteogenic effect of CaP-coated surfaces, compared to Ti [19-21]. Studies attempting to clarify the mechanism behind these beneficial effects have shown that both the chemical composition and surface roughness are of influence on protein adsorption, integrin expression, and subsequently cellular behavior [22-24]. In the present study, the substrates differ in chemical composition, roughness, and morphology, and thus it is not possible to attribute effects on cell behavior to just one of these factors. Therefore, we separated the results of cell cultures on CaP-coated from non coated Ti substrates.
###end p 59
###begin p 60
###xml 955 957 922 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 958 960 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1051 1052 1015 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1054 1056 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1058 1060 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
In the first run, cellular attachment early after seeding was affected on CaP-coated substrates following a pre-treatment with anti-integrin-beta1 or anti-integrin-beta3 antibodies. Furthermore, mRNA expression of integrin-beta1 was increased, and the mRNA expression of integrin-beta3 was decreased. In the second run, initial attachment and total cell amount were decreased when cells were pre-treated with anti-integrin-beta1 or anti-integrin-beta3 antibodies. Moreover, mRNA expression of integrin-beta1 was increased after 3 days of culture, and mRNA expression of integrin-beta3 was decreased, even in the control groups. From these data, it can be deducted that on the ESD-derived CaP-coated substrates mainly integrin-beta1 is responsible for cellular attachment. These results corroborate the available literature, which shows that integrin-beta1 always is highly expressed on CaP-coated substrates, whereas integrin-beta3 is not always present [15-18]. Indeed, many researchers state that integrin-beta1 is the major subunit in osteoblasts [5, 25, 26].
###end p 60
###begin p 61
On non coated Ti substrates, cellular attachment was not affected by the blocking procedure in the first run. Still, mRNA expression of integrin-beta1 was upregulated, and mRNA of integrin-beta3 was decreased. In the second run, again attachment was not affected by a pre-treatment with anti-integrin-beta1 antibodies. However, early cellular attachment was decreased when cells were pre-treated with anti-integrin-beta3 antibodies. The mRNA expression of integrin-beta1 was increased after 3 days of culture, and the mRNA of integrin-beta3 was increased after 1 day of culture. These results suggest an involvement of integrin-beta1 and integrin-beta3 in the attachment of osteoblast-like cells to non coated Ti. However, in the first run, there is only a small upregulation of mRNA of integrin-beta1, and no effect on cellular attachment, which is the opposite of the results on CaP-coated substrates. Furthermore, in the second run, an increased mRNA of integrin-beta3 was observed, but a decrease in early cellular attachment. On bare Ti, osteoblast-like cells have a considerable ability to compensate for cellular attachment, for example with the upregulation of other integrins.
###end p 61
###begin p 62
###xml 214 216 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1030 1032 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
Besides their role as adhesion molecule, integrins also function as signaling receptors. Integrin-beta1-mediated adhesion to bone matrix induces proliferation, differentiation, and matrix synthesis by osteoblasts [27]. In the present study, after a pre-treatment with either integrin antibody, the mRNA expression of ALP was decreased. This occurred in both runs, and on both types of substrates. Thus it seemed that, despite the increase in mRNA of integrin-beta1 and integrin-beta3, signal transduction necessary for osteogenic differentiation was decreased or at least delayed. It has to be noted that without a pre-treatment with anti-integrin-beta1 or anti-integrin-beta3 antibodies, mRNA expression of ALP was also decreased in cultures on both types of substrates, when day 1 is compared to day 3. These results are supported by other studies. For instance, a decreased ALP activity was observed when antibodies against fibronectin (alpha4beta1 and alpha5beta1) or collagen type I (alpha1beta1 and alpha2beta1) were added [14].
###end p 62
###begin p 63
In conclusion, we can maintain our hypothesis that blocking of integrin-beta1 and integrin-beta3 with antibodies has an inhibitory effect on the attachment and differentiation of osteoblast-like cells. However, osteoblast-like cells have the ability to compensate to great extent for the blocking strategy as applied here. Still, integrin-beta1 and beta3 seem to play different roles in attachment, proliferation, and differentiation of osteoblast-like cells, and responses on CaP-coated substrates differ to non coated Ti. Furthermore, the influence on ALP expression suggests involvement of both integrin subunits in signal transduction for cellular differentiation.
###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
Scanning electron microscopy was performed at the Microscopic Imaging Centre (MIC) of the Nijmegen Centre for Molecular Life Sciences (NCMLS), the Netherlands. This research was supported by the Dutch Technology Foundation STW, grant #NKG.5546.
###end p 65
###begin title 66
References
###end title 66

